These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

232 related items for PubMed ID: 21367665

  • 1. Immune mechanisms of new therapeutic strategies in MS: teriflunomide.
    Claussen MC, Korn T.
    Clin Immunol; 2012 Jan; 142(1):49-56. PubMed ID: 21367665
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. New oral drugs for multiple sclerosis.
    Gasperini C, Ruggieri S.
    Neurol Sci; 2009 Oct; 30 Suppl 2():S179-83. PubMed ID: 19882371
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Teriflunomide (Aubagio®) for the treatment of multiple sclerosis.
    Bar-Or A.
    Exp Neurol; 2014 Dec; 262 Pt A():57-65. PubMed ID: 24925677
    [Abstract] [Full Text] [Related]

  • 8. Identification and development of new therapeutics for multiple sclerosis.
    Linker RA, Kieseier BC, Gold R.
    Trends Pharmacol Sci; 2008 Nov; 29(11):558-65. PubMed ID: 18804288
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. From Leflunomide to Teriflunomide: Drug Development and Immunosuppressive Oral Drugs in the Treatment of Multiple Sclerosis.
    Aly L, Hemmer B, Korn T.
    Curr Neuropharmacol; 2017 Nov; 15(6):874-891. PubMed ID: 27928949
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Teriflunomide (AUBAGIO). Multiple sclerosis: just a metabolite of leflunomide.
    Prescrire Int; 2015 Mar; 24(158):61-4. PubMed ID: 25897452
    [Abstract] [Full Text] [Related]

  • 18. [TERIFLUNOMIDE: A NEW ORAL IMMUNOMODULATING AGENT FOR MULTIPLE SCLEROSIS].
    Bencsik K, Rózsa C, Vécsei L.
    Ideggyogy Sz; 2015 Mar 30; 68(3-4):79-87. PubMed ID: 26434194
    [Abstract] [Full Text] [Related]

  • 19. Synthesis of novel therapeutic agents for the treatment of multiple sclerosis: a brief overview.
    Mulakayala N, Rao P, Iqbal J, Bandichhor R, Oruganti S.
    Eur J Med Chem; 2013 Feb 30; 60():170-86. PubMed ID: 23291119
    [Abstract] [Full Text] [Related]

  • 20. Teriflunomide for the treatment of relapsing-remitting multiple sclerosis.
    Miller AE.
    Expert Rev Clin Immunol; 2015 Feb 30; 11(2):181-94. PubMed ID: 25511008
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.